OR WAIT null SECS
The acquisition will expand Nexelis’ immunology testing expertise.
On March 4, 2020, Nexelis, a portfolio company of Ampersand Capital Partners and a provider of assay development and advanced laboratory testing, announced that it has signed a definitive agreement to acquire ImmunXperts, a Brussels, Belgium-based immunogenicity and immune-oncology testing laboratory. The transaction is expected to close by the end of March. Financial details of the deal were not disclosed.
ImmunXperts has developed and performs a full offering of immunogenicity and immuno-oncology in-vitro functional and potency assays, which help pharmaceutical and biotech sponsors screen, select, and optimize lead compounds before the initiation of in-vivo trials.
“ImmunXperts’ immunology testing expertise will help Nexelis more broadly serve the needs of our customers,” said Benoit Bouche, Nexelis president and CEO, in a company press release. “Nexelis will now have an unrivaled ability to efficiently develop immunogenicity assays, qualify and validate them in a regulated environment, and then ultimately perform them utilizing our high-throughput platforms in support of clinical trials.”
“We are proud of ImmunXperts’ achievements over the past five years and are grateful for the support obtained from our investors and partners, our employees, and the Wallonia region. We are excited to continue our growth trajectory as part of Nexelis and serve as a European hub for the company,” added Sofie Pattijn, chief technology officer, and Thibault Jonckheere, CEO, ImmunXperts, in the press release. Both Pattijn and Jonckheere will continue in senior leadership roles at Nexelis.